Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 165Polycystic Ovary Syndrome 23Neoplasm Metastasis 9Osteoporosis 7Neoplasms 6Infertility 6Endometrial Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Ovarian Neoplasms 4Breast Carcinoma In Situ 4Arthralgia 4Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Recurrence 2Pain 2Leiomyoma 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2Carcinoma, Lobular 2Bone Diseases, Metabolic 2Uterine Neoplasms 1Patient Acceptance of Health Care 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Neoplastic Cells, Circulating 1

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × Letrozole × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡